Frequently Asked Questions

Answers to Common Questions About the ASTRA Study

Thank you for your interest in the ASTRA clinical study. Choosing whether to participate in a clinical study is an important decision. Below are answers to common questions based on the IRB-approved study protocol and Informed Consent Form. Your study doctor will discuss additional details and answer any further questions you may have.

FAQ List

The study is evaluating the safety and potential effectiveness of an investigational therapy for corneal swelling caused by corneal endothelial dysfunction.
AURN001 is an investigational cell therapy made from human cultured donor endothelial cells combined with a medication that helps the cells attach and survive.
Not necessarily. Participants are randomly assigned to receive AURN001 or the control solution.
No. The study is double-masked. Neither you nor the study doctors evaluating your eye will know which treatment group you are in.
About 12 months, with approximately 10–11 scheduled follow-up visits.
Yes. Only one eye will receive the study treatment. The other eye will be monitored throughout the study.
Because your vision may be blurry or fluctuate after the procedure, you should not plan to drive yourself home. Your study doctor will let you know when it is safe to resume driving based on how your eye is healing.
You may be evaluated for rescue treatment, which could be a corneal transplant (PK or EK), depending on study criteria and your study doctor’s judgment.
Risks may include discomfort, inflammation, infection, increased eye pressure, or worsening of corneal swelling. Full details are provided in the Informed Consent Form.
Benefits cannot be guaranteed. The study is evaluating whether AURN001 may reduce swelling and improve clarity.
Corneal endothelial cells help keep the cornea clear by removing excess fluid. When these cells do not function properly, fluid can build up inside the cornea and cause swelling (corneal edema).
If enough endothelial cells are lost or damaged, the cornea cannot stay compact. Fluid may accumulate, leading to swelling, hazy vision, or fluctuating vision throughout the day.
Swelling can change throughout the day based on activities, environment, or how much fluid the cornea absorbs. As swelling increases or decreases, vision may become clearer or hazier at different times.
Yes. The study site will explain compensation details during screening.
Only authorized members of the study team, the study sponsor, the IRB, and regulatory agencies may review your study-related medical information. Your personal information will be protected and handled according to privacy laws. The Informed Consent Form provides full details.
No. Participation is voluntary, and you may leave the study at any time. Declining to participate will not affect your usual medical care.
Check Eligibility

Find a Study Doctor

The ASTRA study is being conducted at selected ophthalmology centers. Study doctors can guide participants through screening and next steps.
Find a Study Doctor

AURN001 is investigational and not approved by the FDA. Participation is voluntary, and you may leave the study at any time. Declining to participate will not affect your standard medical care.